Nuvectis Pharma Inc NVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVCT is a good fit for your portfolio.
News
-
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
-
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
-
Nuvectis Pharma to Present at the 36th Annual Roth Conference
-
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
-
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
-
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
-
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
-
Nuvectis Gets FDA Orphan Designation for NXP800 in Cholangiocarcinoma
Trading Information
- Previous Close Price
- $6.51
- Day Range
- $6.43–6.61
- 52-Week Range
- $6.30–18.65
- Bid/Ask
- $6.48 / $6.51
- Market Cap
- $115.50 Mil
- Volume/Avg
- 21,307 / 95,228
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 13
- Website
- https://www.nuvectis.com
Comparables
Valuation
|
Metric
|
NVCT
|
IMVT
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 9.29 | 5.93 | 16.65 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
NVCT
IMVT
DYN
Financial Strength
|
Metric
|
NVCT
|
IMVT
|
DYN
|
|---|---|---|---|
Quick Ratio | 2.74 | 21.56 | 2.41 |
Current Ratio | 2.75 | 22.14 | 2.53 |
Interest Coverage | — | — | — |
Quick Ratio
NVCT
IMVT
DYN
Profitability
|
Metric
|
NVCT
|
IMVT
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −85.22% | −43.33% | −88.69% |
Return on Equity (Normalized) | −115.93% | −47.83% | −114.25% |
Return on Invested Capital (Normalized) | −120.14% | −52.69% | −102.56% |
Return on Assets
NVCT
IMVT
DYN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pchpzjznf | Fhv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Npgwrnvw | Tjjhzp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dgwdxcfk | Mwfwzc | $97.8 Bil | |
MRNA
| Moderna Inc | Qdbtmsbpb | Zhf | $41.3 Bil | |
ARGX
| argenx SE ADR | Fhhpzmzpd | Bsxlc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vklzggtn | Qqfl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lgmpnvh | Jmzbjh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fcpwzcs | Rqxdbk | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rdbmbqbm | Lldmpc | $12.5 Bil | |
INCY
| Incyte Corp | Syczplyk | Czntxn | $11.6 Bil |